Thursday, October 26th, 2017
1:00 PM – 2:00 PM
Getting better Outcomes with Chimeric Antigen Receptor T-cell therapy (GO–CART): A BioCanRx Research Program to Safely and Effectively Translate CAR-T Cell Therapy for Blood Cancers
CAR-T cell therapy is on the cutting edge of cancer therapeutics and has shown promise in paediatric and adult patients with certain blood cancers such as acute lymphoblastic leukemia and lymphoma.
Join Dr. Harold Atkins to learn about advances in CAR-T cell therapy and how a unique, world-class translational research platform is being developed in Canada to create a clinical trial protocol that is better than any previously designed cellular therapy trial in the CAR-T arena.
Dr. Harold Atkins
Scientist, Cancer Therapeutics Program
Ottawa Hospital Research Institute
Attending Physician, Blood and Marrow Transplant Program
The Ottawa Hospital
Associate Professor, Clinical Hematology
University of Ottawa
Harold Atkins MD is a physician of the Ottawa Hospital Blood and Marrow Transplant Program, an Associate Professor of Medicine at the University of Ottawa, a scientist in the Center for Innovative Cancer Research and the medical director of the Regenerative Medicine Program at the Ottawa Hospital Research Institute.
He specializes in the management of patients requiring stem cell transplantation and he has spearheaded the use of stem cell transplantation for immune repair to treat patients with severe autoimmune diseases, particularly Multiple Sclerosis. He has also developed clinical trials exploring the role of dose escalated radiation therapy to treat refractory blood cancers. His laboratory research includes a longstanding and fruitful collaboration with Dr. John Bell developing oncolytic viruses particularly for the treatment of hematological cancers as personalized cancer cell vaccines.